# A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma

> **NCT03696069** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 501 (actual)

## Conditions studied

- Melanoma

## Interventions

- **OTHER:** Non-Interventional

## Key facts

- **NCT ID:** NCT03696069
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-09
- **Primary completion:** 2019-12-27
- **Final completion:** 2020-02-14
- **Target enrollment:** 501 (ACTUAL)
- **Last updated:** 2022-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03696069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03696069, "A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03696069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*